Plasma levels of omentin in patients with medullary thyroid carcinoma

authors:

avatar Fatemeh Norasti , avatar Marjan Zarif Yeganeh , avatar Sara Sheikholeslami , avatar Laleh Hoghooghi Rad , avatar Hoda Golab Ghadaksaz , avatar Mehdi Hedayati ORCID , *

Koomesh: Vol.21, issue 1; 83-86
published online: March 09, 2019
article type: Research Article
received: September 05, 2017
accepted: June 09, 2018

how to cite: Norasti F, Zarif Yeganeh M, Sheikholeslami S, Hoghooghi Rad L, Golab Ghadaksaz H, et al. Plasma levels of omentin in patients with medullary thyroid carcinoma. koomesh. 2019;21(1):e153041. 

Abstract

Introduction: Medullary thyroid carcinoma (MTC) accounts for 5- 10% of thyroid malignancies. The origin of medullary thyroid cancer is para-follicular cells of the thyroid. Several studies showed that relationship between adipokines and cancers. Omentin is an adipokine secreted from adipose tissue. The aim of this study was to investigate the relationship between plasma levels of omentin in patients with medullary thyroid cancer. Materials and Methods: In this case-control study, 90 individuals were studied (45 cases and 45 controls). Omentin plasma levels of these individuals were measured by ELISA method. Results: In general, plasma levels of omnentin in all patients with MTC was significantly higher than the control group (P = 0.002). Omentin plasma levels in both women and men with MTC were ignificantly higher than the corresponding control group (P = 0.0371, and P = 0.0240, respectively). Conclusion: The results of this study showed that plasma levels omentin in patients with MTV were higher than the healthy group. Thus omentin may be considered as a novel and promising biomarker for diagnosis or confirmation of MTC.

References

  • 1.

    Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol 2016; 12:192-202.

  • 2.

    Figlioli G, Landi S, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res 2013; 752:36-44.

  • 3.

    Hedayati M, ZarifYeganeh M, Sheikholeslami S, Daneshpour M, Azizi F. Medullary thyroid cancer screening Using the RET Proto Oncogene Genetic Marker. Iran J EndocMetab 2015; 17:157-170.

  • 4.

    Figlioli G, Landi S, Romei C, Elisei R, Gemignani F. Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. Mutat Res 2013; 752:36-44.

  • 5.

    Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis.Expert Rev MolDiagn 2008; 8: 83-95.

  • 6.

    Lodish MB, Stratakis CA. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther 2008; 8:625-632.

  • 7.

    Yeganeh MZ, Sheikholeslami S, Hedayati M. RET proto oncogene mutation detection and medullary thyroid carcinoma prevention. Asian Pac J Cancer Prev 2015; 16:2107-2117.

  • 8.

    Yeganeh MZ, Sheikholeslami S, DehbashiBehbahani G, Farashi S, Hedayati M. Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma. TumourBiol2015; 36:5225-5231.

  • 9.

    Leal Vde O, Mafra D. Adipokines in obesity. ClinChimActa 2013;419:87-94.

  • 10.

    Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr2004; 92:347-355.

  • 11.

    Zorlu M, Kiskac M, Cakirca M, Karatoprak C, Guler EM, Celik K, et al. Evaluation of the Relation between Vitamin D and Serum Omentin and Vaspin Levels in Women. ExpClinEndocrinol Diabetes 2016; 124:440-443.

  • 12.

    Szydlo B, Kiczmer P, Swietochowska E, Ostrowska Z. Role of omentin and chemerin in metabolic syndrome and tumor diseases. PostepyHig Med Dosw (Online)2016; 70:844-849.

  • 13.

    Lee CH, Woo YC, Wang Y, Yeung CY, Xu A, Lam KS. Obesity, adipokines and cancer: an update. ClinEndocrinol 2015; 83:147-156.

  • 14.

    Hedayati M, Yaghmaei P, Pooyamanesh Z, ZarifYeganeh M, Hoghooghi Rad L. Leptin: a correlated Peptide to papillary thyroid carcinoma? J Thyroid Res 2011;2011:832163.

  • 15.

    Lotfi J, Taghikhani M, Yeganeh MZ, Sheikholeslami S, Hedayati M. Single nucleotide polymorphism of rs1800247 in promoter region of osteocalcin gene in patients with medullary thyroid carcinoma. J Isfahan Med Sch 2014; 32.(Persian).

  • 16.

    Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 20:143-148.

  • 17.

    Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. HormMolBiolClinInvestig 2015; 21:57-74.

  • 18.

    Morad V, Abrahamsson A, Kjolhede P, Dabrosin C. Adipokines and vascular endothelial growth factor in normal human breast tissue in vivo - correlations and attenuation by dietary flaxseed. J Mammary Gland BiolNeoplasia 2016; 21:69-76.

  • 19.

    Erdogan S, Yilmaz FM, Yazici O, Yozgat A, Sezer S, Ozdemir N, et al. Inflammation and chemerin in colorectal cancer. TumourBiol 2016; 37:6337-6342.

  • 20.

    Ahima RS. Central actions of adipocyte hormones.Trends EndocrinolMetab 2005; 16:307-313.

  • 21.

    Aleksandrova K, di Giuseppe R, Isermann B, Biemann R, Schulze M, Wittenbecher C, et al. Circulating omentin as a novel biomarker for colorectal cancer risk: data from the EPIC-potsdam cohort study. Cancer Res 2016; 76:3862-3871.

  • 22.

    Uyeturk U, Sarici H, Kin Tekce B, Eroglu M, Kemahli E, Uyeturk U, et al. Serum omentin level in patients with prostate cancer. Med Oncol2014; 31:923.

  • 23.

    Fazeli MS, Dashti H, Akbarzadeh S, Assadi M, Aminian A, Keramati MR, et al. Circulating levels of novel adipocytokines in patients with colorectal cancer. Cytokine 2013; 62:81-85.

  • 24.

    Shen XD, Zhang L, Che H, Zhang YY, Yang C, Zhou J, et al. Circulating levels of adipocytokine omentin-1 in patients with renal cell cancer. Cytokine 2016;77:50-55.

  • 25.

    Cheng SP, Chi CW, Tzen CY, Yang TL, Lee JJ, Liu TP, et al. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma. Surgery 2010; 147:847-853.

  • 26.

    Cheng SP, Liu CL, Hsu YC, Chang YC, Huang SY, Lee JJ. Regulation of leptin receptor expression in human papillary thyroid cancer cells.Biomed Pharmacother 2012; 66:469-473.

  • 27.

    Cheng SP, Yin PH, Hsu YC, Chang YC, Huang SY, Lee JJ, et al. Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways. Oncol Rep 2011; 26:1265-1271.